Lenvatinib + Capecitabine
Phase 1WithdrawnDevelopment Stage
Advanced Cancer
Advanced Cancer, Malignant Neoplasm of Breast, Malignant Neoplasms of Bone and Articular Cartilage, Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Independent (Primary) Multiple Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Malignant Neoplasms of Male Genital Organs, Malignant Neoplasms of Mesothelial and Soft Tissue, Malignant Neoplasms of Respiratory and Intrathoracic Organs, Malignant Neoplasms of Thyroid and Other Endocrine Glands, Malignant Neoplasms of Urinary Tract
Dec 1, 2016 → —
About Lenvatinib + Capecitabine
Lenvatinib + Capecitabine is a phase 1 stage product being developed by Eisai for Advanced Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02915172. Target conditions include Advanced Cancer, Malignant Neoplasm of Breast, Malignant Neoplasms of Bone and Articular Cartilage.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Cancer were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02915172 | Phase 1 | Withdrawn |
Competing Products
20 competing products in Advanced Cancer